FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200363917> ?p ?o ?g. }

• W4200363917 endingPage "854" @default.
• W4200363917 startingPage "841" @default.
• W4200363917 abstract "The application of hepatitis B virus (HBV)-T-cell receptor (TCR) T-cell immunotherapy in patients with HBV-related hepatocellular carcinoma (HBV-HCC) has been apathetic, as the expression of HBV antigens by both normal HBV-infected hepatocytes and HCC cells with HBV-DNA integration increases the risk of on-target off-tumor severe liver inflammatory events. To increase the safety of this immunotherapeutic approach, we developed messenger RNA (mRNA) HBV-TCR-redirected T cells that-due to the transient nature of mRNA-are functionally short lived and can be infused in escalating doses. The safety of this approach and its clinical potential against primary HBV-HCC have never been analyzed in human trials; thus, we studied the clinical and immunological parameters of 8 patients with chronic HBV infection and diffuse nonoperable HBV-HCC treated at weekly intervals with escalating doses (1 × 104 , 1 × 105 , 1 × 106 , and 5 × 106 TCR+ T cells/kg body weight) of T cells modified with HBV-TCR encoding mRNA. The treatment was well tolerated with no severe systemic inflammatory events, cytokine storm, or neurotoxicity observed in any of these patients throughout treatment. Instead, we observed a destruction of the tumor lesion or a prolonged stable disease in 3 of 8 patients. Importantly, the patients without clinically relevant reductions of HCC did not display any detectable peripheral blood immunological alterations. In contrast, signs of transient localized liver inflammation, activation of the T-cell compartment, and/or elevations of serum chemokine (C-X-C motif) ligand (CXCL) 9 and CXCL10 levels were detected in patients with long-term clinical benefit. Conclusion: We show that despite the reduced in vivo half-life (3-4 days), adoptive transfer of mRNA HBV-TCR T cells into patients with HBV-HCC show long-term clinical benefit that was associated with transient immunological alterations." @default.
• W4200363917 created "2021-12-31" @default.
• W4200363917 creator A5001426004 @default.
• W4200363917 creator A5003515662 @default.
• W4200363917 creator A5003924230 @default.
• W4200363917 creator A5011853295 @default.
• W4200363917 creator A5019899138 @default.
• W4200363917 creator A5025064842 @default.
• W4200363917 creator A5027445044 @default.
• W4200363917 creator A5031735069 @default.
• W4200363917 creator A5034071601 @default.
• W4200363917 creator A5039286311 @default.
• W4200363917 creator A5043613667 @default.
• W4200363917 creator A5043667362 @default.
• W4200363917 creator A5044804183 @default.
• W4200363917 creator A5059405939 @default.
• W4200363917 creator A5061175474 @default.
• W4200363917 creator A5061325966 @default.
• W4200363917 creator A5061388769 @default.
• W4200363917 creator A5072357964 @default.
• W4200363917 creator A5080294797 @default.
• W4200363917 creator A5081093007 @default.
• W4200363917 creator A5083242662 @default.
• W4200363917 date "2021-12-21" @default.
• W4200363917 modified "2023-10-17" @default.
• W4200363917 title "Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC" @default.
• W4200363917 cites W2012392646 @default.
• W4200363917 cites W2027828064 @default.
• W4200363917 cites W2252614391 @default.
• W4200363917 cites W2737143554 @default.
• W4200363917 cites W2786403629 @default.
• W4200363917 cites W2802499642 @default.
• W4200363917 cites W2804015468 @default.
• W4200363917 cites W2810310469 @default.
• W4200363917 cites W2905137137 @default.
• W4200363917 cites W2914462041 @default.
• W4200363917 cites W2992577051 @default.
• W4200363917 cites W2993190047 @default.
• W4200363917 cites W3044786201 @default.
• W4200363917 cites W3108478127 @default.
• W4200363917 cites W3150736119 @default.
• W4200363917 cites W4210774372 @default.
• W4200363917 doi "https://doi.org/10.1002/hep4.1857" @default.
• W4200363917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34935312" @default.
• W4200363917 hasPublicationYear "2021" @default.
• W4200363917 type Work @default.
• W4200363917 citedByCount "5" @default.
• W4200363917 countsByYear W42003639172022 @default.
• W4200363917 countsByYear W42003639172023 @default.
• W4200363917 crossrefType "journal-article" @default.
• W4200363917 hasAuthorship W4200363917A5001426004 @default.
• W4200363917 hasAuthorship W4200363917A5003515662 @default.
• W4200363917 hasAuthorship W4200363917A5003924230 @default.
• W4200363917 hasAuthorship W4200363917A5011853295 @default.
• W4200363917 hasAuthorship W4200363917A5019899138 @default.
• W4200363917 hasAuthorship W4200363917A5025064842 @default.
• W4200363917 hasAuthorship W4200363917A5027445044 @default.
• W4200363917 hasAuthorship W4200363917A5031735069 @default.
• W4200363917 hasAuthorship W4200363917A5034071601 @default.
• W4200363917 hasAuthorship W4200363917A5039286311 @default.
• W4200363917 hasAuthorship W4200363917A5043613667 @default.
• W4200363917 hasAuthorship W4200363917A5043667362 @default.
• W4200363917 hasAuthorship W4200363917A5044804183 @default.
• W4200363917 hasAuthorship W4200363917A5059405939 @default.
• W4200363917 hasAuthorship W4200363917A5061175474 @default.
• W4200363917 hasAuthorship W4200363917A5061325966 @default.
• W4200363917 hasAuthorship W4200363917A5061388769 @default.
• W4200363917 hasAuthorship W4200363917A5072357964 @default.
• W4200363917 hasAuthorship W4200363917A5080294797 @default.
• W4200363917 hasAuthorship W4200363917A5081093007 @default.
• W4200363917 hasAuthorship W4200363917A5083242662 @default.
• W4200363917 hasBestOaLocation W42003639171 @default.
• W4200363917 hasConcept C13373296 @default.
• W4200363917 hasConcept C147483822 @default.
• W4200363917 hasConcept C154317977 @default.
• W4200363917 hasConcept C19317047 @default.
• W4200363917 hasConcept C202751555 @default.
• W4200363917 hasConcept C203014093 @default.
• W4200363917 hasConcept C2522874641 @default.
• W4200363917 hasConcept C2776090121 @default.
• W4200363917 hasConcept C2777701055 @default.
• W4200363917 hasConcept C2778019345 @default.
• W4200363917 hasConcept C2780593183 @default.
• W4200363917 hasConcept C502942594 @default.
• W4200363917 hasConcept C55493867 @default.
• W4200363917 hasConcept C5858377 @default.
• W4200363917 hasConcept C71924100 @default.
• W4200363917 hasConcept C86803240 @default.
• W4200363917 hasConcept C8891405 @default.
• W4200363917 hasConceptScore W4200363917C13373296 @default.
• W4200363917 hasConceptScore W4200363917C147483822 @default.
• W4200363917 hasConceptScore W4200363917C154317977 @default.
• W4200363917 hasConceptScore W4200363917C19317047 @default.
• W4200363917 hasConceptScore W4200363917C202751555 @default.
• W4200363917 hasConceptScore W4200363917C203014093 @default.
• W4200363917 hasConceptScore W4200363917C2522874641 @default.
• W4200363917 hasConceptScore W4200363917C2776090121 @default.
• W4200363917 hasConceptScore W4200363917C2777701055 @default.

• next